Published • loading... • Updated
INOVIO Announces Pricing of Approximately $75 Million Public Offering
The company plans to use the proceeds for corporate financing and general purposes, with underwriters able to buy additional shares.
- On Thursday, INOVIO Pharmaceuticals, Inc. announced pricing of a public offering expected to generate approximately $75 million in gross proceeds.
- The company priced 58,747,235 shares of common stock at $1.05 per share and pre-funded warrants to purchase 12,681,337 shares at $1.049 per warrant.
- Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers, while H.C. Wainwright & Co. serves as lead manager.
- The offering is expected to close on or about Monday, November 9, 2026; underwriters hold a 30-day option to purchase up to 10,714,285 additional shares.
- INOVIO focuses on developing DNA medicines for HPV-related diseases and cancer, having filed its shelf registration statement with the SEC in July.
Insights by Ground AI
45 Articles
45 Articles
INOVIO Announces Pricing of Approximately $75 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 5, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing…
Coverage Details
Total News Sources45
Leaning Left7Leaning Right4Center30Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
L 17%
C 73%
Factuality
To view factuality data please Upgrade to Premium
